计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| M414281-1mg |
1mg |
现货 ![]() |
| |
| M414281-5mg |
5mg |
现货 ![]() |
| |
| M414281-25mg |
25mg |
现货 ![]() |
|
| 别名 | 3-((3-(4-((5-异丙基-3-(((2S,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-1H-吡唑-4-基)甲基)-3-甲基苯氧基)丙基)氨基)-2,2-二甲基丙酰胺 |
|---|---|
| 英文别名 | HY-17638 | EX-A4127 | GSK-1614235 free baseDSP-3235 free base | KGA-3235 free base | Propanamide, 3-((3-(4-((3-(beta-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl)methyl)-3-methylphenoxy)propyl)amino)-2,2-dimethyl- | Mizagliflozin [INN:WHO-DD] | |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Mizagliflozin (KWA 0711) |
| 生化机理 | Mizagliflozin (KWA 0711) 是一种新型、强效、选择性钠葡萄糖协同转运体 1 (SGLT1) 抑制剂,对人类 SGLT1 的 Ki 值为 27 nM。Mizagliflozin 的选择性比值(对人 SGLT1 的 Ki 值/对人 SGLT1 的 Ki 值)为 303。Mizagliflozin 具有改善慢性便秘的潜在用途。 |
| 储存温度 | 避光,-20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 钠/葡萄糖共转运体 1 抑制剂 |
| 产品介绍 |
Information Mizagliflozin (KWA 0711) Mizagliflozin (KWA 0711) is a novel, potent, selective sodium glucose co-transporter 1 (SGLT1) inhibitor with Ki of 27 nM for human SGLT1. The selectivity ratio (Ki value for human SGLT2/Ki value for human SGLT1) of mizagliflozin is 303. Mizagliflozin shows the potential use for the amelioration of chronic constipation. Targets human SGLT1 (Cell-free assay) 27 nM(Ki) In vitro Mizagliflozin\'s inhibitory activity against SGLTs is evaluated by an in vitro assay of cells transiently expressing SGLTs. Mizagliflozin potently inhibits human SGLT1 in a highly selective manner.. In vivo The oral administration of Mizagliflozin increased fecal wet weight in a dog model of loperamide-induced constipation and a rat model of low-fiber-diet-induced constipation.. Cell Research(from reference) Cell lines:COS-7 cells Concentrations:0-1 μM, 0-30 μM Incubation Time:1 h |
| 纯度 | ≥98% |
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 2,2-dimethyl-3-[3-[3-methyl-4-[[5-propan-2-yl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1H-pyrazol-4-yl]methyl]phenoxy]propylamino]propanamide |
| INCHI | 1S/C28H44N4O8/c1-15(2)21-19(25(32-31-21)40-26-24(36)23(35)22(34)20(13-33)39-26)12-17-7-8-18(11-16(17)3)38-10-6-9-30-14-28(4,5)27(29)37/h7-8,11,15,20,22-24,26,30,33-36H,6,9-10,12-14H2,1-5H3,(H2,29,37)(H,31,32)/t20-,22-,23+,24-,26+/m1/s1 |
| InChi Key | LREHMKLEOJAVMQ-TXKDOCKMSA-N |
| Smiles | CC1=C(C=CC(=C1)OCCCNCC(C)(C)C(=O)N)CC2=C(NN=C2OC3C(C(C(C(O3)CO)O)O)O)C(C)C |
| Isomeric SMILES | CC1=C(C=CC(=C1)OCCCNCC(C)(C)C(=O)N)CC2=C(NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(C)C |
| 关联CAS | 666843-10-3 |
| PubChem CID | 10460535 |
| MeSH Entry Terms | 3-(3-(4-(3-(glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl)-3-methylphenoxy)propylamino)-2,2-dimethylpropionamide;mizagliflozin |
| 分子量 | 564.67 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL (177.09 mM); Water: 100 mg/mL (177.09 mM); Ethanol: 100 mg/mL (177.09 mM); |
|---|---|
| 敏感性 | 对光线敏感 |
| 分子量 | 564.700 g/mol |
| XLogP3 | 1.500 |
| 氢键供体数Hydrogen Bond Donor Count | 7 |
| 氢键受体数Hydrogen Bond Acceptor Count | 10 |
| 可旋转键计数Rotatable Bond Count | 14 |
| 精确质量Exact Mass | 564.316 Da |
| 单同位素质量Monoisotopic Mass | 564.316 Da |
| 拓扑极表面积Topological Polar Surface Area | 192.000 Ų |
| 重原子数Heavy Atom Count | 40 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 789.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 5 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |